Dutasteride Mesotherapy ruined my hair 8/28/2023
A 30-year-old male experienced worsened hair thinning after trying topical minoxidil/finasteride and then undergoing three sessions of Dutasteride mesotherapy. Despite consistent use of 5% minoxidil, his hair condition deteriorated, and he suspects a shedding phase or adverse reaction to the treatments.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity 3 months on dutasteride/minoxidil progress
A user shared their 3-month progress using 0.5mg daily dutasteride and 3mg oral minoxidil for hair loss, reporting significant improvement after an initial shedding phase. The user experienced no side effects and noted that dutasteride might have fewer side effects than finasteride.
community 6 months on minoxidil shedding again
A user experienced hair shedding after six months of using topical minoxidil and is considering adding finasteride to their routine. Many suggest that minoxidil alone is insufficient for stopping hair loss and recommend combining it with finasteride or dutasteride for better results.
community Prolonged shedding over last 15 months
The user has been experiencing prolonged hair shedding despite using Dutasteride, Minoxidil, and topical Finasteride, with blood tests showing high free testosterone and low SHBG. Suggestions include adjusting Minoxidil dosage, considering topical anti-androgens like RU58841, and addressing metabolic factors to increase SHBG.
community So what’s really the deal with dutasteride hairline ruining claims?
The potential effects of dutasteride on hair loss, with some users reporting it improved their hairline while others experienced worsened hair loss or shedding. Other treatments discussed include minoxidil and finasteride, as well as RU58841.
community 31M – 4.5 months progress fin&min&dut meso
A 31-year-old male shared his 4.5-month progress using finasteride, topical minoxidil, and dutasteride mesotherapy for hair loss, showing significant improvement in crown density and overall hair texture. He reported no side effects and plans to continue the treatment to assess further results.
Related Research
6 / 6 resultsresearch The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms
This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.
research Managing patterned hair loss – a hair raising task!
This review summarizes existing knowledge on diffuse and patterned alopecia, emphasizing recent advancements in treatment beyond FDA-approved options, but it reports no new clinical findings.
research Androgenetic Alopecia: Therapy Update
This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
research Safety concerns when using novel medications to treat alopecia
This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.
research Nonsurgical Therapy for Hair Loss
This review discusses current and emerging medical therapies for androgenetic alopecia but reports no new clinical findings, emphasizing the importance of stabilizing the condition as a complement to surgical hair restoration.
research Platelet‐rich plasma with low dose oral minoxidil (1.25mg versus 2.5mg) along with trichoscopic pre‐ and post‐treatment evaluation
This pilot study found that among male androgenetic alopecia patients, 2.5 mg oral minoxidil with platelet-rich plasma led to higher patient satisfaction than 1.25 mg, though hair count improvements were not statistically significant.